Kistler-Tiffany Companies’s Definium Therapeutics DFTX Stock Holding History

Kistler-Tiffany Companies’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$779	Hold	218	–	–	﹤0.01%	851
2023 Q1	$692	Hold	218	–	–	﹤0.01%	760
2022 Q4	$480	Hold	218	–	–	﹤0.01%	773
2022 Q3	$1K	Hold	218	–	–	﹤0.01%	759
2022 Q2	$2K	Hold	218	–	–	﹤0.01%	717
2022 Q1	$4K	Hold	218	–	–	﹤0.01%	678
2021 Q4	$5K	Hold	218	–	–	﹤0.01%	651
2021 Q3	$8K	Buy	+218	New	+$9.43K	﹤0.01%	610

Other funds holding DFTX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Kistler-Tiffany Companies's DFTX Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Definium Therapeutics (DFTX) position steady in Q2 2023 at 218 shares worth $779. The position accounts for ﹤0.01% of the portfolio, ranked #851.

Kistler-Tiffany Companies first reported a position in DFTX in Q3 2021 and has held it in 8 quarters since. The position peaked at $8K in Q3 2021. 84 funds tracked by Wall St. Rank hold DFTX as of Q2 2023.

Kistler-Tiffany Companies held 218 shares of Definium Therapeutics worth $779 as of Q2 2023.
Kistler-Tiffany Companies left its Definium Therapeutics share count unchanged in Q2 2023.
Definium Therapeutics made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #851 holding.
Kistler-Tiffany Companies first reported a position in Definium Therapeutics in Q3 2021 and has held it in 8 quarters since.
Kistler-Tiffany Companies's Definium Therapeutics position peaked at $8K in Q3 2021.
84 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.